Td Waterhouse Canada Inc. Black Diamond Therapeutics, Inc. Transaction History
Td Waterhouse Canada Inc.
- $15.3 Trillion
- Q3 2025
A detailed history of Td Waterhouse Canada Inc. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Td Waterhouse Canada Inc. holds 300 shares of BDTX stock, worth $1,155. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300
Previous 300
-0.0%
Holding current value
$1,155
Previous $743,000
50.34%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BDTX
# of Institutions
96Shares Held
41.4MCall Options Held
0Put Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$40.5 Million0.02% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$21.6 Million0.73% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$17.1 Million0.91% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$12.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$10.5 Million0.15% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $140M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...